Breaking News

Majority of oncology clinical trials in China failed to meet enrolment

The majority of oncology clinical trials in China that had a start date between 1 January 2012 and 31 December 2017 ...

NHSA partners with Singaporean medtech accelerator

The Northern Health Science Alliance has partnered with Zicom MedTacc in Singapore in a strategic deal, which will see ...

Impact of Japan’s regenerative medicine regulatory reforms

In 2014, the Japanese government introduced a number of regulatory reforms intended to accelerate the development of ...

The contract services and outsourcing industry: a small molecule CDMO perspective

The pharmaceutical outsourcing industry has seen major growth during the past decade; but, with an ever-changing ...

Clover Biopharmaceuticals selects GE’s biomanufacturing platform

The new facility will support a robust pipeline of biopharmaceuticals, including a biosimilar to Enbrelâ for the ...

CBMG accelerates cell therapy manufacturing

GE Healthcare’s new start-to-finish solution — FlexFactory — for cell therapy installation will provide Cellular ...

Eisai enters into agreement with Adlai Nortye for potential anticancer agent

Eisai has entered a licensing agreement granting exclusive rights concerning the research, development, manufacture and ...

Wuxi Griffin – a new aseptic fill contract manufacturer in China

The main focus of the western-managed joint venture will be the aseptic fill and finish of sterile pharmaceuticals

Advancing the chemistry of pharmaceutical manufacturing in Japan

To sustain success, drug developers are increasingly looking to align with outsourcing partners that are able to ...

Putting people at the core of meeting ever increasing healthcare expectation

The World Health Organization (WHO) defined health in its broader sense in its 1948 constitution as “a state of ...

CPhI Japan predicts a transformative year for Japanese pharma

A New Year report from CPhI forecasts 2018 will be a transformative year for Japanese pharma, as the market evolves ...

Heptares enters drug collaboration with Imperial

Heptares, the wholly-owned subsidiary of Sosei Group Corporation, has entered a new drug research and development ...